{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:19:19Z","timestamp":1777580359149,"version":"3.51.4"},"reference-count":19,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of the research<\/jats:title>\n                    <jats:p>This study aimed to evaluate the cost-effectiveness of Brolucizumab in patients with exudative age-related macular degeneration (AMD) and persistent retinal fluid unresponsive to previous therapies, within the context of a real-world clinical practice setting in a Spanish referral hospital. Furthermore, the study examined the probabilities of transitioning between therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Major findings<\/jats:title>\n                    <jats:p>A 6-month treatment projection demonstrated that Brolucizumab was not cost-effective compared to Ranibizumab (incremental cost-effectiveness ratio [ICER]: \u221212.98) and Aflibercept (ICER: \u221247.64). Conversely, when assessing only drug and administration visit costs, Brolucizumab appeared cost-effective (ICER of 9.14 versus Aflibercept and 35.01 versus Ranibizumab). The increased burden of follow-up costs, which were \u20ac348.96 higher than those for Ranibizumab and \u20ac174.48 higher than Aflibercept, likely drove the trend towards non-cost-effectiveness. Additionally, the analysis indicated a 43% probability of transitioning to Faricimab within the studied population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Brolucizumab was determined to be not cost-effective compared to Ranibizumab and Aflibercept in patients with exudative AMD and persistent retinal fluid, primarily due to a higher number of follow-up visits necessitated by its safety profile. Furthermore, newly observed vitreous opacities and a tendency towards the use of Faricimab were noted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/11206721251388170","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:12:07Z","timestamp":1761048727000},"page":"231-239","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness analysis of Brolucizumab compared to Aflibercept and Ranibizumab in nAMD with persistent retinal fluid"],"prefix":"10.1177","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9604-2970","authenticated-orcid":false,"given":"Ricardo","family":"Garc\u00eda-Serrano Fuertes","sequence":"first","affiliation":[{"name":"Hospital Virgen del Roc\u00edo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s","family":"Romero Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Hospital Virgen del Roc\u00edo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2795-1482","authenticated-orcid":false,"given":"Jes\u00fas","family":"Suarez P\u00e9rez","sequence":"additional","affiliation":[{"name":"Hospital Virgen del Roc\u00edo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9354-3802","authenticated-orcid":false,"given":"Fernando","family":"L\u00f3pez Herrero","sequence":"additional","affiliation":[{"name":"Hospital Virgen del Roc\u00edo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarita","family":"Caban\u00e1s Jim\u00e9nez","sequence":"additional","affiliation":[{"name":"Hospital Virgen del Roc\u00edo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4578-1748","authenticated-orcid":false,"given":"Antonio","family":"Flores C\u00f3rdoba","sequence":"additional","affiliation":[{"name":"Hospital Virgen del Roc\u00edo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Luis","family":"S\u00e1nchez Vicente","sequence":"additional","affiliation":[{"name":"Hospital Virgen del Roc\u00edo"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"e_1_3_2_2_2","first-page":"743","article-title":"Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis","volume":"27","author":"Yu JS","unstructured":"Yu JS, Carlton R, Agashivala N, et al. Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis. J Manag Care Spec Pharm 2021 Jun; 27: 743\u2013752.","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2019-314422"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-305702"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2009.58"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.09.006"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054481"},{"key":"e_1_3_2_8_2","first-page":"814","article-title":"Brolucizumab in pretreated neovascular age-related macular degeneration: case series, systematic review, and meta-analysis","volume":"13","author":"H\u00e4nsli C","unstructured":"H\u00e4nsli C, Schild C, Pfister I, et al. Brolucizumab in pretreated neovascular age-related macular degeneration: case series, systematic review, and meta-analysis. Life (Basel) 2023 Mar 17; 13: 814.","journal-title":"Life (Basel)"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-021-02063-6"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2022.03.024"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2021.06.003"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.04.017"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1159\/000530544"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-023-00445-0"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.11.011"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.3341\/kjo.2023.0133"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.3341\/kjo.2023.0009"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-022-00922-3"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02193-3"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-022-07972-w"}],"container-title":["European Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11206721251388170","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/11206721251388170","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11206721251388170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T19:41:43Z","timestamp":1777405303000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/11206721251388170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1177\/11206721251388170"],"URL":"https:\/\/doi.org\/10.1177\/11206721251388170","relation":{},"ISSN":["1120-6721","1724-6016"],"issn-type":[{"value":"1120-6721","type":"print"},{"value":"1724-6016","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]}}}